Compare Biogen Inc (BIIB) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs MobilEye Global Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while MobilEye Global Inc trades at $8.87 (market cap $7.54B). The key difference: Biogen Inc is far larger — about 4× MobilEye Global Inc's market cap, and Biogen Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | MBLY | |
|---|---|---|
Market Cap | $30.13B | $7.54B |
Sector | Health | Technology |
52-Week High | $216.63 | $15.54 |
52-Week Low | $128.93 | $6.56 |
Enterprise Value | $37.20B | $6.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Mobileye (MBLY) trades at $8.80, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $0.19 versus $0.06 expected, driven by an R&D grant, while revenue reached $508 million (Bloomberg, 2026-07-23). The company faces leadership transition as CEO Amnon Shashua steps down after 27 years, amid expanded robotaxi and ADAS initiatives, including a new supply deal with Stellantis (Business Wire, 2026-07-21).
Outlook: Analyst consensus is bullish with a $11.40 price target (61.5% buy ratings), but risks include persistent net losses (-$4.1B in 2026), high EV/EBITDA of 43.25, and execution challenges under new leadership. The stock offers upside if robotaxi adoption accelerates, but profitability concerns and market volatility pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
